(S)-2-iso-propylpiperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-2-iso-propylpiperidine
• 英文别名: (2R)-2-propan-2-ylpiperidine
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: UGZMDPJPZIDCOA-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-Heptenoic acid,6-methyl-5-[[(1S)-1-phenylethyl](phenylmethyl)amino]-, ethyl ester,(2E,5R)- 在 palladium dihydroxide lithium aluminium tetrahydride 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 为溶剂， 20.0 ℃ 、506.62 kPa 条件下， 反应 36.0h， 生成 (S)-2-iso-propylpiperidine
  参考文献：
  名称：

  β-氨基Weinreb酰胺的不对称合成和应用：（S）-coniine的不对称合成。

  摘要：

  将锂（S）-N-苄基-N-α-甲基苄基酰胺共轭添加到一定范围的α，β-不饱和Weinreb酰胺中会产生高水平的非对映选择性（> 95％de）。通过与格氏试剂反应，可将β-氨基Weinreb酰胺产物转化为β-氨基酮，而用DIBAL-H处理可得到β-氨基醛。通过Wadsworth-Emmons反应和随后的操作捕集醛提供了一条制备高纯手性δ-氨基酸衍生物和2-取代的哌啶的有效途径。证明了该方法在合成（S）-甜菜碱中的应用。

  DOI：

  10.1039/b402531h

文献信息

• Methylphenidate-prodrugs, processes of making and using the same
  申请人：KemPharm, Inc.

  公开号：US10759778B2

  公开（公告）日：2020-09-01

  The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.

  本技术涉及由哌醋甲酯共轭物和未共轭哌醋甲酯组成的组合物。本技术还涉及包含与烟酰-L-丝氨酸共轭的 d-噻吩甲酯和/或其药学上可接受的盐，以及未共轭的哌醋甲酯和/或其药学上可接受的盐的组合物和口服制剂。本技术还涉及一种药物试剂盒，其中包含的组合物包括与烟碱酰-L-丝氨酸共轭的d-苏甲酚和/或其药学上可接受的盐，以及未共轭的哌醋甲酯和/或其药学上可接受的盐。
• Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US11084800B2

  公开（公告）日：2021-08-10

  Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

  本发明提供了补体因子 D 抑制剂、药物组合物及其用途以及制造工艺。所提供的化合物包括式I、式II、式III、式IV和式V，或其药学上可接受的盐、原药、同位素类似物、N-氧化物或分离异构体，可选药学上可接受的组合物。本文所述的抑制剂以因子 D 为靶点，抑制或调节补体级联。
• Degraders and Degrons for targeted protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US11524949B2

  公开（公告）日：2022-12-13

  Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.

  本文介绍了用于治疗的药物降解剂和降解器。
• Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20200071301A1

  公开（公告）日：2020-03-05

  Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
• COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
  申请人：C4 Therapeutics, Inc.

  公开号：US20210198256A1

  公开（公告）日：2021-07-01

  Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.